The meeting abstracts are available from ASN by sending an email to Publications@ASN-Online.org. Scroll down to see citations to this article.
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
The pathogenesis and treatment of hemolytic uremic syndrome.
Jump to section
Cited By...
- Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease
- Shiga Toxin-Producing Escherichia coli O104:H4: a New Challenge for Microbiology
- Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coli
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
- Shiga Toxin 2 and Lipopolysaccharide Induce Human Microvascular Endothelial Cells To Release Chemokines and Factors That Stimulate Platelet Function
- Shiga Toxin 1 Causes Direct Renal Injury in Rats
- Hemolytic Uremic Syndrome
- Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome
- Oral Therapy with a Shiga Toxin-Binding Agent for HUS
- Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries
- Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura
- von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
- Basic Fibroblast Growth Factor among Children with Diarrhea-Associated Hemolytic Uremic Syndrome
- Detection of Verocytotoxin Bound to Circulating Polymorphonuclear Leukocytes of Patients with Hemolytic Uremic Syndrome